Encompass Health Corporation – Consensus ‘buy’ rating and 12.7% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Encompass Health Corporation which can be found using ticker (EHC) have now 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 85 and 71 calculating the average target price we see $80.00. Given that the stocks previous close was at $71.00 and the analysts are correct then there would likely be a percentage uptick in value of 12.7%. There is a 50 day moving average of $66.99 while the 200 day moving average is $60.88. The market cap for the company is 7.08B. The stock price is currently at: 70.66 USD

The potential market cap would be $7,980,480,252 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 25.24, revenue per share of 46.04 and a 6.67% return on assets.

Encompass Health Corporation is a provider of post-acute healthcare service. The Company manages its operations through its inpatient rehabilitation segment. The Company is the owner and operator of rehabilitation hospitals. It operates hospitals in approximately 37 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. The Company operates approximately 156 inpatient rehabilitation hospitals. It provides specialized rehabilitative treatment on an inpatient basis. The Company’s inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It also provides rehabilitative care for patients recovering from injury or illness, using advanced technology and treatments to maximize recovery. Its hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages technologies and advanced therapies and leads to superior outcomes.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search